October 31, 2024 Endocrinologic and Metabolic Drugs Advisory Committee

October 31, 2024 Endocrinologic and Metabolic Drugs Advisory Committee

The Committee will discuss new drug application 210934, for sotagliflozin oral tablet, submitted by Lexicon Pharmaceuticals, Inc., for the proposed indication, as an adjunct to insulin therapy, to improve glycemic control in adults with type 1 diabetes mellitus and chronic kidney disease.

source